Conclusions
In patients diagnosed with KHE/TA, about 40% will exhibit KMP,
confirming established rates. Currently, a lower mortality rate (1.3%)
exists likely owing to earlier recognition and treatment implementation
with improved medical therapy options. Overall treatment response rates
are high at > 70% by 6 months. There was no significant
difference in treatment response or durability of disease response
comparing sirolimus to vincristine. Our results support individualized
treatment decision plans based on disease severity, side effect profile,
patient clinical situation, and physician experience. Response criteria
and response rates reported here will be useful for guiding future
treatment protocols for vascular tumors.